`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________________________
`
`LUPIN LTD., and LUPIN PHARMACEUTICALS INC.
`Petitioners
`
`v.
`
`SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
`BAUSCH & LOMB PHARMA HOLDINGS CORP.
`Patent Owner
`____________________
`
`IPR2015-01099 (US Patent No. 8,669,290)
`____________________
`
`PETITIONERS’ MOTION TO EXPUNGE
`
`
`
`
`
`I.
`
`Introduction
`
`Pursuant to 37 C.F.R. § 42.56, Petitioner Lupin submits this motion to
`
`expunge the previously-sealed versions of: (1) Exhibit 2109 and (2) Exhibit 2082.
`
`Pursuant to the Board’s Order on September 15, 2016 (Paper 70), Petitioner is
`
`authorized to file a motion to expunge confidential information from the records
`
`within 35 days of the entry of the Final Written Decision.1 Patent Owner does not
`
`oppose this motion.
`
`II. Legal Standard
`
`“After denial of a petition to institute a trial or after final judgment in a trial,
`
`a party may file a motion to expunge confidential information from the record.” 37
`
`C.F.R. § 42.56. Under the rules, “information will be made public where the
`
`existence of the information is referred to in a decision to grant or deny a request to
`
`institute review or is identified in a final written decision following a trial.” Trial
`
`Practice Guide, 77 Fed. Reg. at 48,761. Conversely, where confidential
`
`information is not relied on by the Board, that information will generally be
`
`expunged. Volkswagen Grp. of Am. v. Emerachem Holdings, LLC, IPR2014-
`
`01556, Paper No. 61, at 2 (expunging confidential papers where “our consideration
`
`of the Subject Papers and Exhibits was not necessary for our determination of
`
`
`1 Sealed copies of Exhibit 2109 and Exhibit 2082 appear to have been
`already expunged by the Board, however, in an abundance of caution Petitioner
`hereby moves to expunge Exhibit 2109 and Exhibit 2082.
`
`2
`
`
`
`
`
`whether the challenged claims of the ’911 patent were patentable.”). In other inter
`
`partes review proceedings, the Board has held that confidential research,
`
`development, or commercial information should remain under seal. See Otter
`
`Products, LLC, Petr., IPR2014-01464, Paper No. 28, pp. 2-4 (PTAB Aug. 27,
`
`2015); Greene’s Energy Grp., LLC, Inc. v. Oil States Energy Svcs., LLC, IPR2014-
`
`00216, Paper 27, at 5 (PTAB Sept. 23, 2014); Gnosis, et al. v. South Alabama Med.
`
`Science Found., IPR2013-00117, Paper 39, at 2 (PTAB Oct. 31, 2013); Unified
`
`Patents Inc. v. Dragon Intellectual Property, LLC, IPR2014-01252, Paper 40, at 7
`
`(PTAB Feb. 27, 2015); Microsoft Corp. v. SurfCast, Inc., IPR2013- 00292, Paper
`
`58, at 4 (PTAB Apr. 24, 2014). In Greene’s Energy Group, the Board held that
`
`portions of an exhibit containing confidential financial information should remain
`
`under seal where the proposed redactions were reasonable and the thrust of the
`
`underlying argument or evidence was clearly discernible from the redacted
`
`versions. Greene’s Energy Grp., IPR2014-00216, Paper 27, at 5. Moreover, in
`
`Otter Products, the Board held that it was appropriate to expunge select exhibits in
`
`support of redacted papers where the public release of such exhibits “has not been
`
`published or other made available to the public,” and where public disclosure of
`
`the exhibits “would be commercially harmful.” Otter Products, IPR2014-01464,
`
`Paper No. 28, at 4. Public disclosure of the information that the parties seek to
`
`have expunged would be commercially harmful as explained further below.
`
`3
`
`
`
`
`
`Further, such information is unnecessary to understand the thrust of the Board’s
`
`final written decision.
`
`III. Confidential Documents that Should be Expunged from the Record
`
`Lupin moves to expunge the sealed versions of (1) Exhibit 2109 that
`
`contains Lupin’s Abbreviated New Drug Application (“ANDA”) and (2) Exhibit
`
`2082 (Declaration of Robert O. Williams, III, Ph.D.) that cite to or substantially
`
`describe the confidential information in Exhibit 2109. Because public disclosure of
`
`the contents of these documents, or descriptions of those contents, would disclose
`
`confidential business information in a highly competitive market, Petitioner
`
`requests that the sealed versions of Exhibit 2109 and Exhibit 2082 be expunged.
`
`This information has not been published and is not publicly available.
`
`A.
`
`Exhibit 2109
`
`As explained in Petitioner’s motion to seal (Paper 63) the sealed version of
`
`Exhibit 2109 is Lupin’s ANDA, which was filed confidentially with the FDA in
`
`order to obtain FDA approval to market Lupin’s generic pharmaceutical product.
`
`The information the parties seek to seal contains Lupin’s highly sensitive,
`
`confidential development information and technical, business information. Lupin’s
`
`product has not yet been marketed and remains confidential.
`
`This exhibit is not cited or discussed in the Board’s Final Written Decision
`
`(Paper 69), therefore, the public can understand the thrust of the Board’s decision
`
`4
`
`
`
`
`
`without resorting to the information contained in Exhibit 2109. If Lupin’s
`
`confidential information is made public, Lupin’s competitors could exploit its
`
`confidential information and gain an unfair competitive advantage over Lupin.
`
`Accordingly, Petitioner requests that Exhibit 2109 be expunged.
`
`B.
`
`Exhibit 2082
`
`As explained in Petitioner’s motion to seal (Paper 63), the Williams
`
`Declaration (Exhibit 2082) describes the confidential information contained in the
`
`ANDA (Exhibit 2109) in connection with secondary considerations of
`
`nonobviousness. In particular, paragraph 201 cites to Exhibit 2109, and the chart at
`
`paragraph 234 shows the generic bromfenac product components described in
`
`Exhibit 2109, and the Final Written Decision (Paper 69) does not cite or rely on
`
`paragraphs 201 or 234 of Exhibit 2082. If Lupin’s confidential information is made
`
`public, Lupin’s competitors could exploit its confidential information and gain an
`
`unfair competitive advantage over Lupin. A redacted copy of Exhibit 2082 has
`
`been filed and will remain in the record, so expunging the aforementioned
`
`confidential information will not impede public understanding of the underlying
`
`arguments and evidence. Accordingly, Petitioner requests that the sealed copy of
`
`Exhibit 2082 be expunged.
`
`5
`
`
`
`
`
`IV. Conclusion
`
`For the foregoing reasons, Petitioner respectfully requests that the Board
`
`expunge the sealed version of Exhibit 2109 and Exhibit 2082. The previously filed
`
`redacted version of Exhibit 2082 should remain publicly available. Expungement
`
`will protect the parties’ confidential and competitively sensitive technical and
`
`commercial information without comprising the public’s ability to understand the
`
`underlying arguments and evidence, because (1) redacted copies of Exhibit 2082
`
`would remain in the record and because (2) the information contained in the
`
`redacted paragraphs of Exhibit 2082 and the information in Exhibit 2109 is
`
`unnecessary to understanding the Board’s rationale in its Final Written Decision.
`
`Respectfully submitted,
`
`/Deborah Yellin/
`Deborah Yellin, Lead Counsel
`Reg. No. 45,904
`CROWELL & MORING LLP
`Intellectual Property Group
`1001 Pennsylvania Avenue, N.W.
`Washington, DC 20004-2595
`Telephone: (202) 624-2947
`Fax: (202) 628-8844
`
`Counsel for Petitioners
`
`
`
`
`
`6
`
`Date: October 17, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATION OF SERVICE
`
`Pursuant to 37 C.F.R. §§ 42.6(e), 42.8(b)(4) and 42.105, the undersigned
`
`certifies that on the 17th day of October, 2016, a complete copy of the foregoing
`
`Petitioners’ Motion to Expunge was served on Patent Owner’s counsel of record at
`
`Patent Owner
`Bryan.Diner@finnegan.com
`Justin.Hasford@finnegan.com
`Joshua.Goldberg@finnegan.com
`
`Respectfully submitted,
`
`
`
`/Shannon M. Lentz/
`Shannon M. Lentz
`Reg. No. 65,382
`CROWELL & MORING LLP
`Intellectual Property Group
`P.O. Box 14300
`Washington, DC 20044-4300
`
`the following:
`
`
`
`
`October 17, 2016
`
`
`
`7